Theralink Blog

Latest Blog Entries

Into the Thick of It: Next-Generation Proteomics (NGPᵀᴹ)

Theralink is a Next-Generation Proteomics (NGPᵀᴹ) company. What does this even mean???? Well first, let’s bake a cake!   Step 1: Find a recipe Step 2: Gather the ingredients Step 3: Make the batter Step 4: Bake in the Oven   Every one of these steps is necessary to get us our perfect and delicious … Continue reading Into the Thick of It: Next-Generation Proteomics (NGPᵀᴹ)

Theralink Enhanced Vehicles – CAR-T and CAR-NK

Chimeric Antigen Receptor (CAR) therapy is the modification of a patient’s immune cells so that they target cancer cells.  In the case of T-cells and CAR-T therapy, cells are taken from a patient’s blood and modified to include a special receptor (CAR receptor) that binds to a specific protein on the patient’s cancer cells. Scientists … Continue reading Theralink Enhanced Vehicles – CAR-T and CAR-NK

The Big 3: AKT-mTOR, Ras-MAPK, JAK-STAT

Today we will be diving into cross-talk between the Big 3 canonical pathways in cancer research: AKT-mTOR, Ras-MAPK, and JAK-STAT. Up to 70% of all human tumors have upregulated mTORC1 function and several oncogenes and/or tumor suppressors have been linked to mTOR signaling. Consequently, most cancer therapeutic strategies target mTOR signaling by way of AKT … Continue reading The Big 3: AKT-mTOR, Ras-MAPK, JAK-STAT

Into the I/O: A immuno-oncology PD1/PDL1 Case Study

Today let’s look into Immuno-oncology (I/O)- particularly using PD1/PDL1 as a case study! With several companies turning to I/O and immuno-therapy for cancer therapeutics, we offer several upstream and downstream targets of interest for patient stratification! One frequent question from our clients is that: “It’s a cool technology, but how can it benefit my PD-1/PD-L1 … Continue reading Into the I/O: A immuno-oncology PD1/PDL1 Case Study

The Theralink Assay

Theralink Technologies is a molecular profiling and precision medicine oncology company specializing in patented, biomarker assay services. We use quantitative Laser Capture Microdissection (LCM) and Reverse Phase Protein Array (RPPA) technology to support therapeutic development from discovery through clinical trials. This patented technology offers Next Generation Proteomics (NGP)TM services that produce in-depth broad-scale signalling analysis … Continue reading The Theralink Assay